Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study

BACKGROUND: Apatinib, a vascular endothelial growth factor receptor (VEGFR) blocker, has demonstrated encouraging antitumor activities and tolerable toxicities in various cancer types. Recurrent or metastatic adenoid cystic carcinoma of the head and neck (R/MACCHN) carries a poor prognosis, and trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Guopei, Zhang, Lin, Dou, Shengjin, Li, Rongrong, Li, Jiang, Ye, Lulu, Jiang, Wen, Dong, Minjun, Ruan, Min, Yang, Wenjun, Zhang, Chenping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111556/
https://www.ncbi.nlm.nih.gov/pubmed/33995600
http://dx.doi.org/10.1177/17588359211013626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111556/
https://www.ncbi.nlm.nih.gov/pubmed/33995600
http://dx.doi.org/10.1177/17588359211013626

Ejemplares similares